Highest-materiality recent filing
LENSAR appoints Michael A. Rossi as Interim CFO; annual meeting set for Aug 4, 2026
Michael A. Rossi appointed Interim CFO effective May 29, 2026, via consulting agreement with Monomoy Advisors at $375/hour.
Recurring revenue rose 9% YoY to $12.6M (94% of total); total system sales fell to $836K from $2.6M.
LENSAR CFO Thomas R. Staab II to resign effective May 8, 2026
CFO Thomas R. Staab II notified company of resignation on April 10, 2026, effective May 8, 2026.
LENSAR Q4 revenue $16.0M (-4% YoY); recurring revenue up 17% to $12.7M
Net loss narrowed to $1.5M ($0.12/sh) from $18.7M loss a year ago, largely on warrant liability fair-value change.
LENSAR terminates merger with Alcon; retains $10M deposit; FTC intended to challenge deal
Merger agreement terminated effective March 16, 2026; FTC intended to seek injunction.
LENSAR secures $9.2M revolving credit facility from Wells Fargo secured by brokerage account
Revolving, non-purpose margin facility secured by a first-priority lien on a designated brokerage account at Wells Fargo.
LENSAR enters $50M revolving credit facility with Wells Fargo secured by brokerage account
Revolving non-purpose margin credit facility up to $50M, secured by first-priority lien on a designated brokerage account at Wells Fargo.
LENSAR acquisition by Alcon faces FTC second request; closing expected H1 2026
LENSAR and Alcon continue cooperating with FTC on Second Request and review.
LENSAR stockholders elect three Class II directors, ratify PwC as auditor at 2025 annual meeting
Nicholas T. Curtis elected with 14,344,298 votes FOR, 1,101,660 WITHHELD, 2,067,913 broker non-votes.
LENSAR Q3 revenue $14.3M, net loss $3.7M; ALLY installed base grows 77% YoY
Revenue $14.3M, +6% YoY; net loss $3.7M ($0.31/share) vs $1.5M loss in Q3 2024.
LENSAR sets Dec 18 2025 annual meeting, contingent on pending Alcon merger not closing first
Annual meeting scheduled for December 18, 2025; record date October 24, 2025.
LENSAR Q2 revenue up 10% to $13.9M; ALLY placements surge; Alcon merger on track
Q2 2025 revenue $13.9M (+10% YoY); procedure volume up 23% to 52,100.
LENSAR stockholders approve merger with Alcon Research
15,983,846 votes for the merger, 26,033 against, 5,113 abstentions; 80.69% quorum.
FTC issues Second Request for LENSAR-Alcon merger, extending HSR waiting period
LENSAR and Alcon each received a Second Request from the FTC regarding the pending merger.
LENSAR Q1 revenue $14.2M (+34% YoY); net loss $27.3M on warrant liability
Total revenue $14.2M vs $10.6M in Q1 2024, driven by system sales and 33% procedure volume growth.
LENSAR Q1 revenue up 34% to $14.2M; net loss $27.3M on warrant liability adjustment
Total revenue $14.2M (+34% YoY); recurring revenue $11.5M (81% of total).
Alcon acquires LENSAR for $14.00/share cash plus CVR up to $2.75, total ~$430M
Per-share consideration: $14.00 cash plus contingent value right (CVR) of up to $2.75 if 614,000 cumulative procedures achieved by Dec 31, 2027.
LENSAR Q4 revenue $16.7M (+38% YoY); positive Adj. EBITDA; ALLY placements surge
Q4 revenue $16.7M, up 38% YoY; full-year revenue +27% YoY to ~$54M (implied).
LENSAR Q3 revenue $13.5M (+38% YoY); 24 ALLY placements; adj. EBITDA positive
Total revenue $13.5M, up 38% YoY; procedure volume +29% worldwide.
LENSAR Reports Q2 2024 Results with 17 ALLY Placements and Terminates Oertli Development Agreement
Q2 2024 revenue $12.6M, up 5% YoY; net loss $9.0M vs $8.8M loss in Q2 2023.
On May 25, 2026, the Board of Directors (the “Board”) of LENSAR, Inc. (the “Company”) appointed Michael A. Rossi to serve as the Company’s Interim Chief Financial Officer and principal financial officer, effective as of May 29, 2026.
Max materiality 0.95 · Median 0.70 · Most common event earnings